Why the study?
Does native T1 mapping discriminate between hypertrophic cardiomyopathy and hypertensive heart disease?
Does native T1 mapping discriminate between hypertrophic cardiomyopathy and hypertensive heart disease?
Native T1 mapping shows potential as an imaging biomarker to differentiate between hypertrophic cardiomyopathy and hypertensive heart disease, and to identify early changes in genotype-positive/phenotype-negative individuals.
Requires prospective validation before clinical differentiation of HCM from hypertensive heart disease; leaves open early detection utility in G+P- subjects.
Native T1 may be applied to discriminate between HCM and hypertensive heart disease and detect early changes in G+P- subjects.
No takes yet. Share an insight, caveat, or question.
Hinojar et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: